The trial intends to study the safety and efficacy of Remaxol® (succinate + methionine +
inosine + nicotinamide; POLYSAN Ltd., Russia),solution for infusion for the reduction of
hyperbilirubinemia in patients with obstructive jaundice caused by tumor (malignancy).